Clinical Trial

Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS) ("Biophytis" or the…

3 months ago

National Organization for Rare Disorders (NORD) Announces $85,000 in Grant Funding for Amyloidosis and Levy-Yeboa Syndrome

QUINCY, Mass., Sept. 30, 2024 /PRNewswire/ -- Today, the National Organization for Rare Disorders (NORD®) announced two new requests for proposal…

3 months ago

Piramal Pharma Solutions Announces $80M Expansion Plan for Sterile Injectables Facility in Lexington, Kentucky

$80M investment plan will add commercial scale sterile injectables capabilities Expansion will significantly increase production capacity and operational efficiency  Lexington facility…

3 months ago

Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System

An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker…

3 months ago

HeartX Cardiovascular Accelerator Announces Four Startup Companies Selected for the 2024 Program

BENTONVILLE, Ark., Sept. 30, 2024 /PRNewswire/ -- HeartX, powered by HealthTech Arkansas and MedAxiom — along with numerous leading cardiology practices…

3 months ago

MeMed BV Test Demonstrates Antibiotic Overuse Reduction in First US Interventional Trial

—First Multi-Center Randomized Controlled Clinical Trial in the US to Show MeMed BV's Impact on Reducing Unnecessary Antibiotics, Supporting Clinical…

3 months ago

Emmes Group recognized as a top EDC platform by Everest Group

Emmes Group named a 'Major Contender' in the Life Sciences Electronic Data Capture (EDC) Products PEAK Matrix® Assessment 2024 from…

3 months ago

NervGen Pharma Provides Update on Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Target enrollment in the chronic cohort close to completionVancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - NervGen Pharma Corp.…

3 months ago

Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403

CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the…

3 months ago